Advancing Pediatric Rhabdomyosarcoma Therapeutics: FGFR4, MYOD1, and Novel Degrader Strategies Take Center Stage
Key Insights
A recent Paediatric Therapeutic Development Workshop highlighted FGFR4 (search), MYOD1 (search), ROR2 (search), P300/CBP (search), and PAX3::FOXO1 (search) as high-priority therapeutic targets in rhabdomyosarcoma (search), a devastating pediatric cancer with 20–30% overall survival in highest-risk groups.
FGFR4 (search)-directed CAR T-cell therapies have entered clinical trials (NCT06865664), while antibody-drug conjugates targeting FGFR4 and ROR2 (search) demonstrate substantial preclinical activity, offering new immunotherapy and ADC-based treatment avenues.
Workshop participants reached strong consensus that MYOD1 (search) degraders should be developed, given universal dependency on wildtype MYOD1 across rhabdomyosarcoma (search) subtypes and the dire prognosis associated with the MYOD1^L122R mutation.
A recent Paediatric Therapeutic Development Workshop convened to address one of pediatric oncology's most formidable challenges—rhabdomyosarcoma (search)—has illuminated a transformative frontier of molecular targets and therapeutic strategies poised to reshape treatment paradigms. Published in the British Journal of Cancer, the workshop report synthesizes current understanding of key oncogenic drivers and charts a course for precision-targeted interventions in a disease where frontline therapy has remained largely unchanged for four decades.
Rhabdomyosarcoma (search), the most common soft tissue sarcoma in children, is currently stratified by genomic profiles rather than purely histological features. Embryonal rhabdomyosarcoma (ERMS) accounts for approximately 60% of pediatric cases, while alveolar rhabdomyosarcoma (ARMS), a poor-prognosis subtype, represents 20% and is frequently characterized by PAX3/7::FOXO1 fusion genes. Spindle cell/sclerosing rhabdomyosarcoma (SCRMS) constitutes 3–10% of cases. Outcomes remain starkly divided: patients in the lowest-risk groups achieve approximately 90% overall survival, whereas those in the highest-risk groups face only 20–30% overall survival. As one parent at the workshop poignantly stated, "survivors are alive but not living a life," underscoring the urgent need for innovative therapeutics that both extend survival and improve quality of life.
FGFR4 (search): A Pivotal Receptor with Clinical Momentum
Fibroblast growth factor receptor 4 (FGFR4 (search)) has emerged as a central therapeutic target, functioning as a downstream transcriptional target of PAX::FOXO1 fusion proteins while also implicated in fusion-negative disease. Studies confirm high FGFR4 expression in primary rhabdomyosarcoma (search) tumors compared with pediatric control tissues, with overexpression correlating with advanced-stage cancer and poor survival. Two hotspot mutations in the tyrosine kinase domain—N535K and V550L/M/E—confer constitutive receptor activity and are present in up to 7.5% of primary tumors, associated with greater metastatic potential and poorer overall survival.
Efforts to target the N535K mutation have encountered early drug resistance, and no specific inhibitors are yet available for the V550 variants. Nevertheless, chimeric antigen receptor (CAR) T-cell therapies directed against FGFR4 (search) are now being evaluated in clinical trials (NCT06865664), marking a critical translational milestone. Antibody-drug conjugates (ADCs) targeting FGFR4 have also demonstrated substantial preclinical activity, though they remain earlier in development.
The workshop highlighted a compelling rationale for dual targeting of FGFR4 (search) and the insulin-like growth factor 1 receptor (IGF1R (search)). PAX3-FOXO1 directly regulates both receptors within a shared oncogenic transcriptional program, and FGFR4 signaling has been shown to rescue tumor cells from apoptosis induced by IGF1R-PI3K-mTOR pathway inhibition. Clinical experience with single-agent IGF1R antibodies such as R1507 and cixutumumab produced only occasional objective responses with limited durability, reinforcing the case for combination strategies. FGFR4-driven rhabdomyosarcoma (search) models demonstrate high sensitivity to PI3K/mTOR inhibition, further supporting this synergistic approach.
MYOD1 (search): A Universal Dependency and Unmet Therapeutic Need
MYOD1 (search) represents a multifaceted target with distinct considerations across rhabdomyosarcoma (search) subtypes. In ERMS and ARMS, wildtype MYOD1 is functionally perturbed, stalling differentiation and sustaining proliferation without mutation. In SCRMS, the MYOD1^L122R mutation—present in approximately 40% of cases—confers MYC-like oncogenic properties and portends a dire prognosis, frequently co-occurring with RAS and PI3K pathway mutations.
Data from the Cancer Dependency Map (DepMap) demonstrate strong selective dependency on wildtype MYOD1 (search) across rhabdomyosarcoma (search) cell lines when targeted using CRISPR, suggesting universal dependency on this transcription factor. Workshop participants reached a strong consensus that a MYOD1 degrader should be developed, noting that no reported academic or commercial programs are currently pursuing this target. Concerns regarding potential toxicity were partially allayed by observations that MyoD1 knockout mice do not display somatic effects, and redundancy exists within the myogenic regulatory network, particularly with Myf5.
ROR2 (search) and Epigenetic Targets Expand the Arsenal
ROR2 (search), a receptor tyrosine kinase-like orphan receptor involved in non-canonical WNT5A signaling, has garnered attention for its role in modulating cell polarity, proliferation, and migration. Despite being traditionally labeled a pseudokinase, ROR2 can homodimerize and autophosphorylate upon WNT5A binding. Notably, ROR2-directed ADCs and CAR T-cell therapies have already progressed into early-phase clinical trials in other malignancies, including head and neck and renal cancers. Preclinical investigations indicate that ROR2-targeted ADCs demonstrate in vitro activity against very poor-prognosis rhabdomyosarcoma (search) harboring MYOD1 (search)^L122R mutations, with potential for synergy with chemotherapy.
The epigenetic regulators P300 and CBP, paralogous histone acetyltransferases recruited by PAX3::FOXO1 (search) fusion proteins to potentiate oncogenic transcriptional programs, represent another promising avenue. Rhabdomyosarcoma (search) cells have shown sensitivity to inhibition of both the bromodomain and histone acetyltransferase domains of P300/CBP (search). The most clinically advanced P300/CBP inhibitor, inobrodib, is currently in Phase II trials in adults with hematological cancers but has not yet been evaluated in rhabdomyosarcoma. Workshop participants encouraged engagement with existing pharmaceutical pipelines rather than de novo drug development, given the breadth of therapeutics already targeting these proteins.
Confronting the Fusion Protein Challenge
PAX3::FOXO1 (search) and PAX7::FOXO1 fusion proteins remain very high-priority yet challenging targets. As nuclear transcription factors with intrinsically disordered structures, they lack clear druggable sites for conventional small molecule inhibition. However, PAX3::FOXO1 degraders are in active preclinical development through initiatives including the KOODAC Cancer Grand Challenge and NIH consortia. Alternative modalities discussed include intracellular single-domain antibodies (iDAbs), molecular glues, antisense oligonucleotides, and T-cell receptor-engineered T-cells—though the latter faces obstacles from deficient MHC class I antigen presentation in fusion-positive tumors, potentially addressable through adjunctive HDAC inhibitors.
Downstream in the Hippo signaling axis, YAP and TAZ transcriptional coactivators have been functionally validated as targets. YAP suppression via shRNA inhibited cell growth and induced apoptosis in ERMS models, while TAZ suppression blocked tumor growth and prolonged survival in murine xenograft models of ARMS. Small molecules targeting TEAD transcription factor hydrophobic pockets are advancing through early clinical stages, and TEAD degraders may offer enhanced efficacy. The intersection of Hippo and Notch pathways further invites combinatorial targeting approaches.
The workshop's findings signal a transformative epoch in rhabdomyosarcoma (search) therapy, with precision-targeted strategies ranging from receptor-directed immunotherapies to innovative degrader platforms and epigenetic modulators holding promise for improved outcomes in this aggressive pediatric cancer.